Skip to main content
PLOS One logoLink to PLOS One
. 2024 Feb 8;19(2):e0292646. doi: 10.1371/journal.pone.0292646

Association between systemic immune-inflammation index and chronic kidney disease: A population-based study

Lin Li 1, Kunfei Chen 2, Chengping Wen 1, Xiaoqin Ma 1,*,#, Lin Huang 1,*,#
Editor: Innocent Ijezie Chukwuonye3
PMCID: PMC10852278  PMID: 38329961

Abstract

Background

Systemic immune-inflammation index (SII) is a new indicator of inflammation, and chronic kidney disease (CKD) has a connection to inflammation. However, the relationship between SII and CKD is still unsure. The aim of this study was whether there is an association between SII and CKD in the adult US population.

Methods

Data were from the National Health and Nutrition Examination Survey (NHANES) in 2003–2018, and multivariate logistic regression was used to explore the independent linear association between SII and CKD. Smoothing curves and threshold effect analyses were utilized to describe the nonlinear association between SII and CKD.

Results

The analysis comprised 40,660 adults in total. After adjusting for a number of factors, we found a positive association between SII and CKD [1.06 (1.04, 1.07)]. In subgroup analysis and interaction tests, this positive correlation showed differences in the age, hypertension, and diabetes strata (p for interaction<0.05), but remained constant in the sex, BMI, abdominal obesity, smoking, and alcohol consumption strata. Smoothing curve fitting revealed a non-linear positive correlation between SII and CKD. Threshold analysis revealed a saturation effect of SII at the inflection point of 2100 (1,000 cells/μl). When SII < 2100 (1,000 cells/μl), SII was an independent risk element for CKD.

Conclusions

In the adult US population, our study found a positive association between SII and CKD (inflection point: 2100). The SII can be considered a positive indicator to identify CKD promptly and guide therapy.

Introduction

Chronic kidney disease (CKD) is a chronic disease manifested by renal impairment, with high morbidity and mortality imposing a heavy burden on public health [1, 2]. With an estimated prevalence ranging from 11–13% worldwide, CKD is a growing concern. Inflammation is one of those main factors responsible for the onset of cancers [3, 4]. The identification of modifiable factors is essential for the prevention of CKD, the delay of target organ damage, and the retardation of disease progression.

Systemic inflammation is a routine part of regular blood tests, a variety of biochemical or hematological indicators and ratios to identify signs of inflammation. Among these markers is the Systemic Immune-Inflammation Index (SII), which provides an inflammation composite index of peripheral lymphocyte, neutrophil and platelet counts. This new marker has gained popularity as it reflects not only the local immune response but also the systemic inflammation [57]. The SII has been tied to the occurrence and propagation of numerous cancers and has proven to be a valuable prognostic factor in cancer patients. Growing tumors are detected and engaged by the immune system, and in recent years, the seventh hallmark of cancer has been recognized to be the immune response and inflammation [8, 9]. In addition to tumors, SII has predictive value for cardiovascular diseases, neurological disorders, metabolic diseases, respiratory diseases, rheumatic diseases, etc [1016]. SII has been shown to be positively associated with a number of kidney-related diseases. For example, SII has been positively associated with severe acute kidney injury [17] and prognosis in patients with renal cell carcinoma [18].

The potential correlation between SII and CKD is yet to be elucidated. Thus, we carried out a population-based cross-sectional investigation for search for the link between the SII and CKD in adults who took part in the National Health and Nutrition Examination Survey (NHANES).

Materials and methods

Data sources

Our study’s data came from NHANES, a database of surveys put together by the Centers for Disease Control and Prevention (CDC). Participants are selected using a special sampling method, and their health and nutrition status are assessed. These results allow us to gain insight into the health and nutritional situation of the US public. Ethics review committees approve all study procedures, which are conducted every two years. Informed consent was obtained from participants before participation in the study. Interviews, physical examinations, and tests on blood and urine samples are all components of the investigation of NHANES. The mobile testing laboratory performed both physical and laboratory exams, and the interviews took place at the participants’ houses. Participants in our data were recruited and participated in data and sample collection by CDC from 2003–2018. And this cross-sectional study was conducted in March 2023, and the information about individual participants was not identifiable during or after data collection.

Study population

For the survey, we pooled data from 8 cycle years 2003–2018 and removed 14,444 subjects with missing SII data, 6,028 subjects with missing CKD data and 19,180 subjects under 20 years of age from the eligible population of 80,312. The selected participants in this study totaled 40,660 individuals. The sample selection process is visualized in Fig 1.

Fig 1. Flowchart of participant selection.

Fig 1

NHANES, National Health and Nutrition Examination Survey.

CKD

According to the Collaborative Epidemiology of Chronic Kidney Disease equation, CKD is indicated by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 or urine albumin-creatinine ratio (ACR) ≥ 30 mg/g [19]. Creatinine and urinary albumin were detected by Jaffe rate method and fluorometric immunoassay, respectively. The following is the eGFR calculation used by the CKD-Epidemiology Collaboration [20]:

eGFRCKD-EPI=141×minScr/κ,1α×maxScr/κ,11:209×0:993Age×1:018iffemale×1:159ifblack

Scr, which denoted serum creatinine concentration (mg/dL). The ACR was calculated using urine albumin/urine creatinine. Additionally, when the individual is female, κis 0.7 andαis -0.329, and when male,κis 0.9 andαis -0.411.

SII

In this study, SII served as the independent variable, which was obtained by multiplying platelet count with the neutrophil count/lymphocyte count ratio. Using a CoulterDxH 800 analyzer, an automated hematology measurement instrument, these three blood cell types were examined and reported as 103 cells/mL.

Covariates

In our study, covariates such as gender, age, race, marital status, education level, income poverty ratio, BMI, abdominal obesity, alcohol drinking, smoking, hypertension, and diabetes mellitus were considered. Race was divided into non-Hispanic white, non-Hispanic black, non-Hispanic Mexican-American, other Hispanic, and other races. Education level was classified as less than high school, high school or more than high school. Three divisions of the income-to-poverty ratio were established: 1.5, 1.5–3.5, and > 3.5. Marital status was classified into three groups: married/live with partner, widowed/divorced/separated, or never married. Drinking status was classified into 5 categories: never, former, mild, moderate, and heavy. For instance, individuals who had consumed < 12 drinks in their lifetime were defined as never drinkers, while former drinkers were those who had consumed ≥ 12 drinks in 1 year and did not drink last year. Mild, moderate, and heavy drinkers were defined based on the frequency and amount of alcohol consumption [21, 22]. Smoking status was Smoking status was divided into former, current, never smoker. People who had never smoked were defined as those who had never smoked ≥ 100 cigarettes in their lifetime, and those who had smoked ≥ 100 cigarettes but stopped smoking were defined as former smoker, and current smokers who were smoked intermittently or continuously smoked ≥ 100 cigarettes [23, 24]. Three BMI ranges were determined: below 25kg/m2, 25–29.9 kg/m2, and 30kg/m2 and above. Abdominal obesity was defined as having a waist circumference ≥ 88 cm for women and ≥ 102 cm for males [25]. Hypertension was diagnosed if the mean systolic and diastolic were > 140 mmHg and/or 90 mmHg, respectively, after three measurements. Based on whether diabetic medications were taken, diabetes was diagnosed [26]. And the information about individual participants was not identifiable both during or after data collection.

Statistical analysis

To evaluate the relationship between SII and CKD, we divided SII into quartiles varying from Q1 to Q4. The mean and standard deviation (SD) is used to describe a measure of continuous variables, whereas the percentage is used to describe a measure of categorical variables. Using weighted t-tests and weighted chi-square tests, we compared the differences between subjects grouped by SII quartiles and between subjects with or without CKD. To construct multivariate tests, we used multivariate logistic regression analysis between SII and CKD, with three models: Model 1 (without covariates), Model 2 (adjusted for age, sex, and race), and Model 3 (adjusted for all covariates). Odds ratio (OR) and 95% confidence interval (CI) were used in the models to assess SII and CKD. To perform sensitivity testing, we conducted subgroup analyses based on age, sex, BMI, abdominal obesity, alcohol consumption, smoking, hypertension, and diabetes. The nonlinear association and inflection point of SII with CKD were also investigated using smoothing curve fitting and threshold effect analysis models. R studio (version 4.2.2) and EmpowerStats (version 2.0) were used for all statistical analyses. P values of less than 0.05 were regarded as significant.

Results

Baseline characteristics of participants

Following the established criteria, 40,660 participants were involved in this study. Of these, 48.33% male and 51.67% female, with 49.77 ± 18.04 years on average. The ethnic breakdown was as follows: 20.66% Mexican American, 39.98% non-Hispanic white, 24.17% non-Hispanic black, 7.77% other Hispanic, and 7.42% other races. SII ± mean SD concentration was 550.60 ± 378.90 and 7447 patients with CKD, representing 18.32% of the total participants.

Table 1 shows that the presence of CKD showed statistically significant associations with various factors such as age, gender, race, education level, poverty, marital status, BMI, waist circumference, alcohol drinking and smoking status, hypertension, diabetes, and SII (p < 0.05). Compared to non-CKD, patients with CKD tend to be older, female, non-Hispanic white, less educated, widowed/divorced/separated, poor, BMI >30kg/m2, abdominal obesity, less heavy drink, more former smoking history, more hypertension, diabetes, and higher levels of SII.

Table 1. Weighted characteristics of the study population categorized by CKD status.

Overall No CKD CKD p-Value
N = 40,660 N = 33213 (81.68%) N = 7447 (18.32%)
Age (Mean ±SD, years) 49.77 ± 18.04 45.09 ± 15.76 61.12 ± 17.37 <0.0001
Gender (%) <0.0001
Male 19653 (48.33%) 48.94 42.78
Female 21007 (51.67%) 51.06 57.22
Race (%) <0.0001
Mexican American 8402 (20.66%) 20.41 22.69
Non-Hispanic White 16256 (39.98%) 40.11 41.52
Non-Hispanic Black 9826 (24.17%) 23.7 24.44
Other Hispanic 3161 (7.77%) 8.39 5.3
Other Race 3015 (7.42%) 7.39 6.05
Education (%) <0.0001
Less than high school 10373 (25.54%) 15.26 23.03
High school 9391 (23.12%) 23.22 26.32
More than high school 20847 (51.33%) 61.52 50.65
Marital status (%) <0.0001
Never married 7168 (17.64%) 18.75 10.39
Maried/Living with Partner 24383 (60.00%) 64.9 57.55
Widowed/Divorced/Separated 9087 (22.36%) 16.35 32.06
Poverty ratio (%) <0.0001
0–1.5 16800 (45.14%) 30.74 39.76
1.5–3.5 9078 (24.39%) 24.96 27.59
>3.5 11336 (30.46%) 44.3 32.65
BMI (kg/m2, %) <0.0001
<25 11656 (29.06%) 30.98 25.59
25–29.9 13373 (33.35%) 33.64 30.16
≥30 15075 (37.59%) 35.38 44.25
Abdominal obesity (%) <0.0001
No 22817 (58.97%) 62.25 48.98
Yes 15874 (41.03%) 37.75 51.02
Drinking status (%) <0.0001
Never 5269 (14.54%) 10.43 15.66
Former 6258 (17.27%) 12.57 23.06
Mild 11979 (33.05%) 36.13 35.84
Moderate 5497 (15.17%) 18.07 12.79
Heavy 7241 (19.98%) 22.8 12.65
Smoking status (%) <0.0001
Never 22277 (54.83%) 55.19 50.51
Former 9948 (24.48%) 23.32 32.83
Now 8406 (20.69%) 21.49 16.66
Hypertension (%) <0.0001
No 23408 (57.58%) 67.41 32.38
Yes 17245 (42.42%) 32.59 67.62
Diabetes (%) <0.0001
No 17167 (78.69%) 88.31 45.93
Yes 4650 (21.31%) 11.69 54.07
SII (Mean±SD,1,000cells/μl) 550.60 ± 378.90 544.73 ± 316.75 625.09 ± 461.88 <0.0001

Continuous variables were expressed as mean ± SD, and P-values were calculated by the weighted linear regression model. Categorical variables are shown as percentages: p-values were calculated by weighted chi-square test. BMI, body mass index; SII, systemic immune-inflammation index; CKD: chronic kidney disease.

Table 2 shows that SII quartiles were observed to have statistically significant (p < 0.05) correlates with age, gender, race, education level, poverty, marital status, BMI, waist circumference, alcohol and smoking status, hypertension, diabetes, and CKD. Compared to Q1, SII participants in the highest quartile Q4 tended to be older, female, non-Hispanic white, less educated, more widowed/divorced/separated, poor, with BMI >30 kg/m2, more abdominal obesity, more heavy drink, more former and current smokers, and more hypertension, diabetes and CKD patients.

Table 2. Weighted characteristics of the study population categorized quartiles of SII.

SII quartiles p-Value
Q1 Q2 Q3 Q4
N = 10160 N = 10165 N = 10169 N = 10166
Age (Mean±SD, years) 46.88 ± 16.98 46.86 ± 16.65 47.28 ± 16.76 48.47 ± 17.39 <0.0001
Gender (%) <0.0001
Male 54.22 49.96 47.43 41.33
Female 45.78 50.04 52.57 58.67
Race (%) 0.0291
Mexican American 20.71 20.19 21.23 20.79
Non-Hispanic White 40.75 39.69 39.89 40.99
Non-Hispanic Black 23.19 24.18 24.3 23.47
Other Hispanic 8.22 8.62 7.55 7.43
Other Race 7.13 7.33 7.03 7.31
Education (%) <0.0001
Less than high school 17.19 15.58 16.14 16.69
High school 22.46 22.21 24.64 25.18
More than high school 60.35 62.21 59.22 58.13
Marital status (%) <0.0001
Never married 18.85 17.06 17.29 17.18
Maried/Living with partner 64.77 65.98 63.83 60.89
Widowed/Divorced/Separated 16.38 16.96 18.88 21.93
Poverty ratio (%) <0.0001
0–1.5 32.4 30.98 31.52 33.24
1.5–3.5 25.76 24.48 25.02 26.14
>3.5 41.84 44.54 43.46 40.61
BMI (kg/m2, %) <0.0001
<25 33.7 31.14 27.59 28.86
25–29.9 34.59 34.6 33.29 30.23
≥30 31.71 34.25 39.11 40.9
Abdominal obesity (%) <0.0001
No 68.26 63.18 58.44 52.57
Yes 31.74 36.82 41.56 47.43
Drinking status (%) <0.0001
Never 12.04 11.18 10.58 10.99
Former 13.11 12.38 14.36 16.24
Mild 37.75 37.78 36.09 32.93
Moderate 16.86 17.91 17.36 17.12
Heavy 20.24 20.75 21.61 22.73
Smoking status (%) <0.0001
Never 56.86 56.63 54.52 50.32
Former 24.73 24.36 23.88 25.79
Now 18.41 19.01 21.61 23.9
Hypertension (%) <0.0001
No 64.59 65.22 62.07 57.92
Yes 35.41 34.78 37.93 42.08
Diabetes (%) <0.0001
No 86.29 84.52 83.03 78.51
Yes 13.71 15.48 16.97 21.49
CKD (%) <0.0001
No 87.73 87.14 86.3 81.76
Yes 12.27 12.86 13.7 18.24

Continuous variables were expressed as mean ± SD, and P-values were calculated by the weighted linear regression model. Categorical variables are shown as percentages: p-values were calculated by weighted chi-square test. BMI, body mass index; SII, systemic immune-inflammation index; CKD: chronic kidney disease.

Association between SII and CKD

Since the effect values were not significant, SII/100 was used to magnify the effect values by a factor of 100. The outcomes obtained from the multivariate regression analysis of SII/100 and CKD are summarized in Table 3. The association was found to be significant in both the unadjusted Model 1 (1.06 (1.05, 1.06)) and the adjusted Model 2 (1.05 (1.04, 1.06)). Adjusted Model 3 showed a significant association of CKD with SII/100 (1.06 (1.04, 1.07)). Sensitivity analysis using SII quartiles is significantly positively correlated in model 1 (1.62 (1.51, 1.74)), model 2 (1.63 (1.51, 1.76)), and Q4 in model 3 (1.61 (1.41, 1.85)) compared to Q1. And for each unit increase in SII in subjects in Q4 compared to Q1, the risk of developing CKD increased by 61% (p for trend < 0.05).

Table 3. Association between SII and CKD.

Crude Model Partially Adjusted Model Fully Adjusted Model
(Model 1) (Model 2) (Model3)
OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
SII/100 1.06 (1.05, 1.06) <0.0001 1.05 (1.04, 1.06) <0.0001 1.06 (1.04, 1.07) <0.0001
SII/100 quartiles
Quartile 1 (0.02–3.36) Reference Reference Reference
Quartile 2 (3.36–4.73) 1.02 (0.95, 1.10) 0.5628 1.05 (0.97, 1.14) 0.1951 0.99 (0.86, 1.15) 0.9409
Quartile 3 (4.73–6.69) 1.17 (1.09, 1.26) <0.0001 1.21 (1.12, 1.31) <0.0001 1.20 (1.05, 1.38) 0.0086
Quartile 4 (6.69–283.97) 1.62 (1.51, 1.74) <0.0001 1.63 (1.51, 1.76) <0.0001 1.61 (1.41, 1.85) <0.0001
p for trend <0.0001 <0.0001 <0.0001

Model 1: no covariates were adjusted.

Model 2: age, gender, and race were adjusted.

Model 3: age, gender, race, marital status, education level, income poverty ratio, BMI, abdominal obesity, drinking status, smoking status, hypertension, and diabetes were adjusted.

We conducted further subgroup analyses to conduct sensitivity analysis. The findings proved that the association between SII and CKD exhibited statistically significant differences in the age, hypertension, and diabetes mellitus subgroups (Fig 2). However, no significant differences were observed in the gender, BMI, abdominal obesity, smoking, or drinking status subgroups. These findings indicate a significant impact of age, hypertension, and diabetes mellitus on the positive association between SII and CKD (P for interaction < 0.05). In addition, gender, BMI, abdominal obesity, smoking, and drinking status had no significant effect on the association (P for interaction>0.05).

Fig 2. Subgroup analysis for the association between SII and CKD.

Fig 2

In the age subgroup analysis, contrary to earlier findings, we discovered that SII had a negative association with CKD in the 30–39 age group [OR (95% CI): 0.97 (0.93, 1.02)]. However, the P values did not demonstrate statistical significance. And the positive association between SII and CKD was more pronounced above the age of 50, especially at 70–79. In addition, when stratified by hypertension or diabetes, our analysis indicated a connection between SII and CKD was more significant in hypertension and diabetes patients compared to those without hypertension and diabetes, respectively.

A smoothed curve fit was utilized to illustrate the nonlinear connection between SII and CKD (Fig 3). Through threshold analysis, it was discovered that SII had a saturation effect at the inflection point of 2100 (1,000 cells/μl). When SII < 2100 (1,000 cells/μl), SII and CKD were positively correlated, and when SII > 2100 (1,000 cells/μl), SII and CKD did not have a statistically distinct connection (Table 4). Therefore, according to this inflection point, it can be suggested that when we further explore the relationship between SII and CKD, it is more appropriate when SII is less than 2000 (1,000 cells/μl).

Fig 3. Association between SII CKD.

Fig 3

Table 4. Threshold effects of SII on CKD analyzed using linear regression models.

Adjusted OR (95% CI), P Value
Fitting by the standard linear model 1.0006 (1.0004, 1.0007) <0.0001
Fitting by the two-piecewise linear model
SII
Inflection point 2100
SII<2100 1.0007 (1.0005, 1.0008) <0.0001
SII>2100 0.9997 (0.9991, 1.0003) 0.3151
Log likelihood ratio 0.004

The red solid line represents the smoothed curve fit linking the variables, while the blue band denotes the corresponding 95% confidence interval.

In addition, we also conducted a statistical analysis of the relationship between CKD stages (G1, G2, G3a, G3b, G4, G5) and SII, as shown in S1, S2 Tables.

Discussion

Our cross-sectional study established a positive link between SII and CKD risk. Moreover, an inflection points of 2100 (1,000 cells/μl) indicated a saturation effect in their association. Subgroup analysis indicated that the correlation between SII and CKD was more significant among hypertension or diabetes, as opposed to participants without hypertension or diabetes. These data findings imply SII is an independent risk factor for CKD when SII is below 2100 (1,000 cells/μl).

Based on literature searches conducted by the authors, our analysis is the first NHANES-based cross-sectional investigation to evaluate the association between SII and CKD in a large population with multiple circulation years. Although the relationship between SII and CKD is not yet clear, the association of SII with kidney-related disease has been demonstrated in clinical studies. A cross-sectional study discovered a beneficial relationship between SII and a high risk of kidney stones in adults under 50 years of age [27]. In a large multicenter longitudinal study, elevated SII was attached to a higher risk of overall mortality and cause-specific death among CKD patients [28]. A retrospective cohort study discovered a J-shaped connection among SII and mortality in critically ill patients with AKI [17]. Ozbek et al retrospectively analyzed 176 patients with renal cell carcinoma who underwent radical nephrectomy and found that SII was linked to increased TNM stage and a poor prognosis [18]. SII has been identified as an independent risk factor and favorable prognostic indicator for metastatic renal cell carcinoma in several studies, especially in patients with BMI ≥ 25 kg/m2, with significant relations with both cancer-specific and overall survival [2934]. Additionally, several retrospective and cohort research has demonstrated that SII is a hazardous indicator of contrast-induced acute kidney injury [3541]. In addition, some studies have used SII as a predictor for the onset of acute kidney injury in diseases such as post-craniotomy in patients with spontaneous cerebral hemorrhage, post-hepatectomy in patients with hepatocellular carcinoma and severe acute pancreatitis, acute coronary syndrome and advanced chronic heart failure [4245].

There is a strong association between inflammation and CKD based on epidemiological studies. A Randomized Controlled Trial (RCT) showed that systemic inflammation may lead to decreased physical function in patients with CKD [46]. Schanstra et al performed a proteomic analysis of 1990 participants from a large multicenter cohort and found that protein fragments linked to CKD progression were mainly derived from proteins involved in inflammation and tissue repair [47]. Additionally, another RCT demonstrated that elevated IL-6 levels were linked to an increased risk of serious adverse cardiovascular events in all stages of CKD [48]. A two-point double-blind trial showed that IL-1 trap therapy reduces systemic inflammation in patients with CKD [49]. One RCT showed that treatment with ticagrelor reduced the inflammatory burden through a reduction in levels of IL-1α, IL-1β, and TNFα in non-dialysis patients with CKD stage 4–5 [50]. According to our research, SII levels and CKD have a positive connection in both model 1, model 2, and model 3. A saturation effect between SII and CKD was observed in the smoothing curve and threshold analysis with an inflection point of 2100 (1000 cells/μL). On the left of the inflection point measurement, a positive association was found. On the right, however, there was no association detected, suggesting a significant threshold effect between SII and CKD. Furthermore, age, hypertension, and diabetes effects on the positive connection between SII and CKD were all statistically different. Our study found a stronger association between SII and CKD in older individuals and patients with hypertension or diabetes. According to several studies, age is an influence on the risk of CKD [51, 52]. In older individuals, increasing age did promote the progression of CKD, and their prevalence of CKD is almost 3–4 times higher than the general population, so screening for CKD in the elderly can be effective [5356]. Many studies have already shown the importance of hypertension and diabetes in promoting the development of CKD [5761].

There is a significant link between inflammation and CKD, although the precise mechanisms underlying this relationship are not fully known. Mendoza et al observed that levels of fibroblast growth factor 23 (FGF23) and several inflammatory markers (such as interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), fibrinogen, and C-reactive protein (CRP)) were increased in CKD [62]. Moreover, each unit increase in FGF23 was linked to more severe inflammation [63]. Kuo et al discovered that pro-inflammatory factors can initiate hyperoxia production in circulating mononuclear cells of CKD patients, resulting in aggravated oxidative stress, which was an essential contributor to systemic inflammation and kidney injury [64]. By increasing the release of interleukin 1 and interleukin 18, NLRP3 inflammatory vesicles have been shown to have a vital function in causing renal inflammation and fibrosis and speeding up the development of CKD [6567]. This promotes the progression of CKD. Sjaarda et al. showed that Uromodulin and human EGF receptor 2 (HER2) are independent pathogenic mediators of CKD, and these biomarkers have potential as targets for the prevention and treatment of CKD [68]. Ruiz et al reported that targeting the transcription factor Nrf2 could reduce CKD-related oxidative stress and inflammatory responses, as this is a crucial aspect of the disease’s pathogenesis [69].

Our survey has several strengths and limitations. The reliability of our study is enhanced by a large nationally representative, multi-ethnic population and appropriate covariate correction. Nonetheless, we need to consider some limitations as well. First of all, observational studies cannot determine the true causality and prospective studies are still required to support it. As this study is a cross-sectional analysis, it may not be possible to establish a definite temporality. Then, the data associated with SII were measured only once, which may underestimate the association. Similarly, since NHANES measured eGFR and uACR values only once, and the potential for acute kidney injury, the definition of CKD may not be precise enough. Furthermore, although we did our best to include appropriate confounders, we still could not exclude the effect of other possible confounders. Finally, the NHANES database limitations prevented the inclusion of drug usage as a covariate in this study, such as nonsteroidal anti-inflammatory drug use in CKD patients. Additionally, the relationship between inflammation and disease is complex and interactions were not accounted for, which may result in our findings not fully reflecting the actual situation.

Conclusion

Our findings indicate a link between SII and CKD. More thorough prospective investigations are required because the results do not prove a causal link.

Supporting information

S1 Table. Weighted characteristics of the study population categorized by 5 stages of CKD.

Continuous variables were expressed as mean ± SD, and P-values were calculated by the weighted linear regression model. Categorical variables are shown as percentages: p-values were calculated by weighted chi-square test. BMI, body mass index; SII, systemic immune-inflammation index; CKD: chronic kidney disease.

(DOCX)

S2 Table. Association between SII and 5 stages of CKD.

Model 1: no covariates were adjusted. Model 2: age, gender, and race were adjusted. Model 3: age, gender, race, marital status, education level, income poverty ratio, BMI, abdominal obesity, drinking status, smoking status, hypertension, and diabetes were adjusted.

(DOCX)

S1 Checklist. STROBE statement—Checklist of items that should be included in reports of observational studies.

(DOCX)

Data Availability

The full set of NHANES data used for this investigation is accessible to the general public here: https://wwwn.cdc.gov/nchs/nhanes.

Funding Statement

This research was funded by Professor Chengping Wen’s Zhejiang Nature Science Foundation (LQ20H270006) and Dr Lin Huang’s National Key R&D Program of China (No. 2018YFC1705500). The funders are involved in research design, data collection and analysis, publication decisions, and manuscript preparation. Chengping Wen: conceptualization, supervision, review manuscripts; Lin Huang: conceptualization, data curation, supervision, review & editing manuscripts.

References

  • 1.Cohen C, Le Goff O, Soysouvanh F, Vasseur F, Tanou M, Nguyen C, et al. Glomerular endothelial cell senescence drives age-related kidney disease through PAI-1. EMBO Mol Med. 2021;13: e14146. doi: 10.15252/emmm.202114146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hu P-J, Chen C-H, Wong C-S, Chen T-T, Wu M-Y, Sung L-C. Influenza vaccination reduces incidence of peripheral arterial occlusive disease in elderly patients with chronic kidney disease. Sci Rep. 2021;11: 4847. doi: 10.1038/s41598-021-84285-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16: 269–288. doi: 10.1038/s41581-019-0248-y [DOI] [PubMed] [Google Scholar]
  • 4.Ebert T, Pawelzik S-C, Witasp A, Arefin S, Hobson S, Kublickiene K, et al. Inflammation and Premature Ageing in Chronic Kidney Disease. Toxins (Basel). 2020;12: 227. doi: 10.3390/toxins12040227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hu L, Yu J, Deng J, Zhou H, Yang F, Lu X. Development of nomogram to predict in-hospital death for patients with intracerebral hemorrhage: A retrospective cohort study. Front Neurol. 2022;13: 968623. doi: 10.3389/fneur.2022.968623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Yang Y-L, Wu C-H, Hsu P-F, Chen S-C, Huang S-S, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50: e13230. doi: 10.1111/eci.13230 [DOI] [PubMed] [Google Scholar]
  • 7.Bartl T, Bekos C, Postl M, Alexander R, Polterauer S, Stefanie A, et al. The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer. J Gynecol Oncol. 2021;32: e1. doi: 10.3802/jgo.2021.32.e1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017;27: 96–108. doi: 10.1038/cr.2016.149 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22: 329–360. doi: 10.1146/annurev.immunol.22.012703.104803 [DOI] [PubMed] [Google Scholar]
  • 10.Xiao S, Wang Z, Zuo R, Zhou Y, Yang Y, Chen T, et al. Association of Systemic Immune Inflammation Index with All-Cause, Cardiovascular Disease, and Cancer-Related Mortality in Patients with Cardiovascular Disease: A Cross-Sectional Study. J Inflamm Res. 2023;16: 941–961. doi: 10.2147/JIR.S402227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shi S, Kong S, Ni W, Lu Y, Li J, Huang Y, et al. Association of the Systemic Immune-Inflammation Index with Outcomes in Acute Coronary Syndrome Patients with Chronic Kidney Disease. J Inflamm Res. 2023;16: 1343–1356. doi: 10.2147/JIR.S397615 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bao Y, Wang L, Du C, Ji Y, Dai Y, Jiang W. Association between Systemic Immune Inflammation Index and Cognitive Impairment after Acute Ischemic Stroke. Brain Sci. 2023;13: 464. doi: 10.3390/brainsci13030464 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Xu J, Guo W, Ma J, Ma Q, Chen J, Song H, et al. Preceding transient ischemic attack was associated with functional outcome after stroke thrombectomy: A propensity score matching study. J Cereb Blood Flow Metab. 2023; doi: 10.1177/0271678X231167924 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mahemuti N, Jing X, Zhang N, Liu C, Li C, Cui Z, et al. Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015–2020). Nutrients. 2023;15: 1177. doi: 10.3390/nu15051177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang R-H, Wen W-X, Jiang Z-P, Du Z-P, Ma Z-H, Lu A-L, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front Immunol. 2023;14: 1115031. doi: 10.3389/fimmu.2023.1115031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu B, Wang J, Li Y-Y, Li K-P, Zhang Q. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999–2018. Arthritis Res Ther. 2023;25: 34. doi: 10.1186/s13075-023-03018-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jia L, Li C, Bi X, Wei F, Meng J, Sun G, et al. Prognostic Value of Systemic Immune-Inflammation Index among Critically Ill Patients with Acute Kidney Injury: A Retrospective Cohort Study. J Clin Med. 2022;11: 3978. doi: 10.3390/jcm11143978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ozbek E, Besiroglu H, Ozer K, Horsanali MO, Gorgel SN. Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma. Int Urol Nephrol. 2020;52: 1455–1463. doi: 10.1007/s11255-020-02440-y [DOI] [PubMed] [Google Scholar]
  • 19.Prevalence of Chronic Kidney Disease and Poor Diagnostic Accuracy of Dipstick Proteinuria in Human Immunodeficiency Virus-Infected Individuals: A Multicenter Study in Japan—PubMed. [cited 19 Apr 2023]. https://pubmed.ncbi.nlm.nih.gov/30320149/ [DOI] [PMC free article] [PubMed]
  • 20.Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150: 604–612. doi: 10.7326/0003-4819-150-9-200905050-00006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hicks CW, Wang D, Matsushita K, Windham BG, Selvin E. Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults: A Prospective Cohort Study. Ann Intern Med. 2021;174: 167–174. doi: 10.7326/M20-1340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rattan P, Penrice DD, Ahn JC, Ferrer A, Patnaik M, Shah VH, et al. Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population. Hepatol Commun. 2022;6: 399–410. doi: 10.1002/hep4.1803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yang Y, Peng N, Chen G, Wan Q, Yan L, Wang G, et al. Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events. Cardiovasc Diabetol. 2022;21: 14. doi: 10.1186/s12933-022-01447-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri M-A, Morris PB, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. Journal of the American College of Cardiology. 2018;72: 3332–3365. doi: 10.1016/j.jacc.2018.10.027 [DOI] [PubMed] [Google Scholar]
  • 25.Liu B, Du Y, Wu Y, Snetselaar LG, Wallace RB, Bao W. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011–18: population based study. BMJ. 2021;372: n365. doi: 10.1136/bmj.n365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.González HM, Tarraf W, González KA, Fornage M, Zeng D, Gallo LC, et al. Diabetes, Cognitive Decline, and Mild Cognitive Impairment Among Diverse Hispanics/Latinos: Study of Latinos–Investigation of Neurocognitive Aging Results (HCHS/SOL). Diabetes Care. 2020;43: 1111–1117. doi: 10.2337/dc19-1676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lai W, Xie Y, Zhao X, Xu X, Yu S, Lu H, et al. Elevated systemic immune inflammation level increases the risk of total and cause-specific mortality among patients with chronic kidney disease: a large multi-center longitudinal study. Inflamm Res. 2023;72: 149–158. doi: 10.1007/s00011-022-01659-y [DOI] [PubMed] [Google Scholar]
  • 28.Di X, Liu S, Xiang L, Jin X. Association between the systemic immune-inflammation index and kidney stone: A cross-sectional study of NHANES 2007–2018. Front Immunol. 2023;14: 1116224. doi: 10.3389/fimmu.2023.1116224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yücel KB, Yekedüz E, Karakaya S, Tural D, Ertürk İ, Erol C, et al. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors. Sci Rep. 2022;12: 16559. doi: 10.1038/s41598-022-20056-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zapała Ł, Ślusarczyk A, Garbas K, Mielczarek Ł, Ślusarczyk C, Zapała P, et al. Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study. Front Biosci (Schol Ed). 2022;14: 5. doi: 10.31083/j.fbs1401005 [DOI] [PubMed] [Google Scholar]
  • 31.Laukhtina E, Pradere B, D’Andrea D, Rosiello G, Luzzago S, Pecoraro A, et al. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urol Nephrol. 2022;74: 329–336. doi: 10.23736/S2724-6051.21.04023-6 [DOI] [PubMed] [Google Scholar]
  • 32.Wang Q, Zhu S-R, Huang X-P, Liu X-Q, Liu J-B, Tian G. Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25: 1302–1310. doi: 10.26355/eurrev_202102_24834 [DOI] [PubMed] [Google Scholar]
  • 33.Chrom P, Zolnierek J, Bodnar L, Stec R, Szczylik C. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. Int J Clin Oncol. 2019;24: 526–532. doi: 10.1007/s10147-018-01390-x [DOI] [PubMed] [Google Scholar]
  • 34.Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016;7: 54564–54571. doi: 10.18632/oncotarget.10515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zhu Y, Qiu H, Wang Z, Shen G, Li W. Predictive value of systemic immune-inflammatory index combined with CHA2DS2-VASC score for contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Int Urol Nephrol. 2023. doi: 10.1007/s11255-023-03571-8 [DOI] [PubMed] [Google Scholar]
  • 36.Ma K, Qiu H, Zhu Y, Lu Y, Li W. Preprocedural SII Combined with High-Sensitivity C-Reactive Protein Predicts the Risk of Contrast-Induced Acute Kidney Injury in STEMI Patients Undergoing Percutaneous Coronary Intervention. J Inflamm Res. 2022;15: 3677–3687. doi: 10.2147/JIR.S370085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lai W, Zhao X, Huang Z, Xie Y, Yu S, Tu J, et al. Elevation of Preprocedural Systemic Immune Inflammation Level Increases the Risk of Contrast-Associated Acute Kidney Injury Following Coronary Angiography: A Multicenter Cohort Study. J Inflamm Res. 2022;15: 2959–2969. doi: 10.2147/JIR.S364915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Karauzum I, Karauzum K, Hanci K, Gokcek D, Kalas B, Ural E. The Utility of Systemic Immune-Inflammation Index for Predicting Contrast-Induced Nephropathy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cardiorenal Med. 2022;12: 71–80. doi: 10.1159/000524945 [DOI] [PubMed] [Google Scholar]
  • 39.Jiang H, Li D, Xu T, Chen Z, Shan Y, Zhao L, et al. Systemic Immune-Inflammation Index Predicts Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Cross-Sectional Study. Front Med (Lausanne). 2022;9: 841601. doi: 10.3389/fmed.2022.841601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ertem AG, Ozen Y, Yuksekkaya B, Akif Erdol M, Erdoğan M, Demirtas K, et al. Association of the Novel Inflammatory Marker Systemic Immune-Inflammation index and Contrast-Induced Nephropathy in Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis. Angiology. 2022;73: 422–430. doi: 10.1177/00033197211045031 [DOI] [PubMed] [Google Scholar]
  • 41.Kelesoglu S, Yilmaz Y, Elcık D, Çetınkaya Z, Inanc MT, Dogan A, et al. Systemic Immune Inflammation Index: A Novel Predictor of Contrast-Induced Nephropathy in Patients With Non-ST Segment Elevation Myocardial Infarction. Angiology. 2021;72: 889–895. doi: 10.1177/00033197211007738 [DOI] [PubMed] [Google Scholar]
  • 42.Wang Q, Li S, Sun M, Ma J, Sun J, Fan M. Systemic immune-inflammation index may predict the acute kidney injury and prognosis in patients with spontaneous cerebral hemorrhage undergoing craniotomy: a single-center retrospective study. BMC Nephrol. 2023;24: 73. doi: 10.1186/s12882-023-03124-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Lu L, Feng Y, Liu Y-H, Tan H-Y, Dai G-H, Liu S-Q, et al. The Systemic Immune-Inflammation Index May Be a Novel and Strong Marker for the Accurate Early Prediction of Acute Kidney Injury in Severe Acute Pancreatitis Patients. J Invest Surg. 2022;35: 962–966. doi: 10.1080/08941939.2021.1970864 [DOI] [PubMed] [Google Scholar]
  • 44.Peng C, Li J, Xu G, Jin J, Chen J, Pan S. Significance of preoperative systemic immune-inflammation (SII) in predicting postoperative systemic inflammatory response syndrome after percutaneous nephrolithotomy. Urolithiasis. 2021;49: 513–519. doi: 10.1007/s00240-021-01266-2 [DOI] [PubMed] [Google Scholar]
  • 45.Wang Z, Qin Z, Yuan R, Guo J, Xu S, Lv Y, et al. Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction. ESC Heart Fail. 2023;10: 478–491. doi: 10.1002/ehf2.14217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Watson EL, Baker LA, Wilkinson TJ, Gould DW, Xenophontos S, Graham-Brown M, et al. Inflammation and physical dysfunction: responses to moderate intensity exercise in chronic kidney disease. Nephrol Dial Transplant. 2022;37: 860–868. doi: 10.1093/ndt/gfab333 [DOI] [PubMed] [Google Scholar]
  • 47.Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJL, Beige J, et al. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. J Am Soc Nephrol. 2015;26: 1999–2010. doi: 10.1681/ASN.2014050423 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, et al. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021;6: 1440–1445. doi: 10.1001/jamacardio.2021.3079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Nowak KL, Chonchol M, Ikizler TA, Farmer-Bailey H, Salas N, Chaudhry R, et al. IL-1 Inhibition and Vascular Function in CKD. J Am Soc Nephrol. 2017;28: 971–980. doi: 10.1681/ASN.2016040453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease—PubMed. [cited 19 Apr 2023]. https://pubmed.ncbi.nlm.nih.gov/36682595/ [DOI] [PMC free article] [PubMed]
  • 51.Factors associated with CKD in the elderly and nonelderly population—PubMed. [cited 19 Apr 2023]. https://pubmed.ncbi.nlm.nih.gov/23085726/ [DOI] [PMC free article] [PubMed]
  • 52.Hallan SI, Stevens P. Screening for chronic kidney disease: which strategy? J Nephrol. 2010;23: 147–155. [PubMed] [Google Scholar]
  • 53.Zhang Q-L, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8: 117. doi: 10.1186/1471-2458-8-117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333: 1047. doi: 10.1136/bmj.39001.657755.BE [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Anderson S, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kaysen GA, et al. Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol. 2009;20: 1199–1209. doi: 10.1681/ASN.2008080860 [DOI] [PubMed] [Google Scholar]
  • 56.Vart P, Reijneveld SA, Bültmann U, Gansevoort RT. Added value of screening for CKD among the elderly or persons with low socioeconomic status. Clin J Am Soc Nephrol. 2015;10: 562–570. doi: 10.2215/CJN.09030914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380: 1649–1661. doi: 10.1016/S0140-6736(12)61272-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Wang Q, Wang Y, Wang J, Zhang L, Zhao M-H. Nocturnal Systolic Hypertension and Adverse Prognosis in Patients with CKD. Clin J Am Soc Nephrol. 2021;16: 356–364. doi: 10.2215/CJN.14420920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, et al. Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2020;15: 200–208. doi: 10.2215/CJN.06600619 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Zelnick LR, Weiss NS, Kestenbaum BR, Robinson-Cohen C, Heagerty PJ, Tuttle K, et al. Diabetes and CKD in the United States Population, 2009–2014. Clin J Am Soc Nephrol. 2017;12: 1984–1990. doi: 10.2215/CJN.03700417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Tang M, Berg A, Rhee EP, Allegretti AS, Nigwekar S, Karumanchi SA, et al. The Impact of Carbamylation and Anemia on HbA1c’s Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease. Diabetes Care. 2023;46: 130–137. doi: 10.2337/dc22-1399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012;7: 1155–1162. doi: 10.2215/CJN.13281211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Stern L. Fibroblast growth factor 23, cardiovascular disease, and inflammation. Clin J Am Soc Nephrol. 2012;7: 1061–1062. doi: 10.2215/CJN.05500512 [DOI] [PubMed] [Google Scholar]
  • 64.Kuo K-L, Hung S-C, Lee T-S, Tarng D-C. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol. 2014;25: 2596–2606. doi: 10.1681/ASN.2013080838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21: 1732–1744. doi: 10.1681/ASN.2010020143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Lorenz G, Darisipudi MN, Anders H-J. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant. 2014;29: 41–48. doi: 10.1093/ndt/gft332 [DOI] [PubMed] [Google Scholar]
  • 67.Rudloff S, Janot M, Rodriguez S, Dessalle K, Jahnen-Dechent W, Huynh-Do U. Fetuin-A is a HIF target that safeguards tissue integrity during hypoxic stress. Nat Commun. 2021;12: 549. doi: 10.1038/s41467-020-20832-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, et al. Blood HER2 and Uromodulin as Causal Mediators of CKD. J Am Soc Nephrol. 2018;29: 1326–1335. doi: 10.1681/ASN.2017070812 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83: 1029–1041. doi: 10.1038/ki.2012.439 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Innocent Ijezie Chukwuonye

28 Jun 2023

PONE-D-23-11993Association between systemic immune-inflammation index and chronic kidney disease: a population-based studyPLOS ONE

Dear Dr. Ma,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

There are some additional corrections that I observed should be made to this manuscript in addition to those observed by the reviewers, and these are reflected in the manuscript attached.

Please submit your revised manuscript by Aug 12 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Innocent Ijezie Chukwuonye, MBBS, FMCP(Internal Medicine)

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors carried out cross-sectional study and conducted multivariate logistic regression and smoothing curves and threshold effect analyses to explore the association between SII and CKD in the adult US population. Concerns with the study design and statistical analysis are as follows:

1.Please analysis the association between CKD stage and SII if GFR data were available

2.The authors found a Inflection point in linear regression models(SI=2100). But a linear trend was found in table 3. Please provide concrete value of each quartile in Table 3

Reviewer #2: This is a novel work, written in a simple style to aid understanding. A few critical points to note:

1. Are the excluded participants systemically different form those included in the study? especially as regards age and gender distribution. This may impact on the CKD classification.

2. The definition of CKD usually requires at least 2 eGFR or uACR values obtained at least 3 months apart. It appears this study had single values for both eGFR and uACR which may affect the classification of CKD. Some of the individuals may have an AKI, thereby causing an overestimation of CKD. AKI, on its own, is an inflammatory condition which may affect SII values. This may invalidate our findings.

3. It appear the 2009 CKD-EPI equation (with race factor) was used for this analysis. This has been shown to inaccurately estimate eGFR. The more recent (and accurate) revision of the equation (DOI: 10.1056/NEJMoa2102953), should be used. The number of participants with CKD will change when the new equation is applied. This is the most important limitation of this study and should be addressed.

4. Is there a statistical trend for SII across the 5 stages of CKD? It would be good to investigate for this.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Manuscript(2).docx

PLoS One. 2024 Feb 8;19(2):e0292646. doi: 10.1371/journal.pone.0292646.r002

Author response to Decision Letter 0


22 Sep 2023

Dear Editor and Reviewers,

We appreciate the opportunity to allow us to revise our manuscript and thanks for reviewers’ constructive comments and suggestions. Firstly, We are very sorry for the delay in revising the draft due to sudden personal problems. Once again, we would like to express my sincere apologies.

We would like to submit our revised manuscript, entitled ‘Association between systemic immune-inflammation index and chronic kidney disease: a population-based study’ for consideration for publication. In the revised manuscript, we have carefully addressed all comments and questions raised by reviewers’ point-by-point. We greatly appreciate your time and efforts to improve our manuscript for publication.

Reply to Reviewers

Reviewer #1:

The authors carried out cross-sectional study and conducted multivariate logistic regression and smoothing curves and threshold effect analyses to explore the association between SII and CKD in the adult US population. Concerns with the study design and statistical analysis are as follows:

1.Please analysis the association between CKD stage and SII if GFR data were available

Reply: Thank you very much for your valuable comments. We re-completed a statistical analysis of the relationship between CKD stage and SII based on GFR data. The new results can be seen in Supplementary Tables 1&2.

2.The authors found a Inflection point in linear regression models(SII=2100). But a linear trend was found in table.

Reply: Thank you for your helpful question, which is well worth investigating. As you proposed, although our curve fitting presents atypical U-shaped or inverted U-shaped associations, inflection points are found in the threshold analysis (p for log-likelihood ratio=0.004). When SII < 2100 (1000 cells/µl), SII was positively correlated with CKD,and SII was an independent risk element for CKD. And when SII > 2100 (1000 cells/µl), there was no statistically significant association between SII and CKD.Therefore, according to this inflection point, it can be suggested that when we further explore the relationship between SII and CKD, it is more appropriate when SII < 2000(1000 cells/µl). The added description is shown in red in the paper.

3. Please provide concrete value of each quartile in Table 3.

Reply: Thank you very much for your professional guidance, which is of great help to our article. We have added specific values for each quartile based on your suggestion in Table 3. (See red in Table 3 for details)

Reviewer #2:

This is a novel work, written in a simple style to aid understanding. A few critical points to note:

1.Are the excluded participants systemically different form those included in the study? especially as regards age and gender distribution. This may impact on the CKD classification.

Reply: Thank you very much for your valuable comments. First, excluded participants included: 1. Missing SII data (14444) 2. Missing CKD data (6028) 3. Age below 20 (19180). Since only adult participants were studied, in the age distribution, subjects younger than 20 years of age were present only in the excluded population. In addition to that, we have made a baseline table of excluded participants(See table below)based on demographic variables such as age/gender/race, showing that the mean age of excluded participants is 13.3 ± 13.4, which is different from that of included adult participants(49.77 ± 18.04) due to the excessive number of excluded participants under the age of 20 (n=19180). Age and gender remained independent risk factors for CKD (P < 0.001). In addition, among excluded participants, CKD patients were mostly white, female,which is consistent with included participants. Due to the low mean age of the excluded participants, the results were mostly those who were Less than high school, never married, more poor, BMI < 25, no abdominal obesity, no smoke, no drink, no hypertension and diabetes. Therefore, in order to achieve objective results without affecting the diagnosis and staging of CKD, participants younger than 20 years of age should be excluded due to their greater impact on the results.

Weighted characteristics of the excluded participation categorized by CKD status.(See the document for the table: Response letter.docx)

Overall No CKD CKD p-Value

N=39652 N= 34339(86.6%) N=5313(13.4%)

Age (Mean ±SD, years) 13.3 ± 13.4 15.65 ± 11.71 17.01 ± 16.24 <0.0001

Gender (%) <0.0001

Male 50.8 53.3 38.01

Female 49.2 46.7 61.99

Race (%) 0.0132

Mexican American 16.5 16.82 16.03

Non-Hispanic White 38.5 34.12 34.21

Non-Hispanic Black 20.7 22.6 23.47

Other Hispanic 9.7 10.68 9.04

Other Race 14.5 15.77 17.25

Education (%) <0.0001

Less than high school 80.6 81.67 85.72

High school 8.4 8.16 5.9

More than high school 11 10.17 8.38

Marital status (%) <0.0001

Never married 55.1 59.9 51.4

Maried/Living with

Partner 32.9 31.13 28.23

Widowed/Divorced

/Separated 12 8.97 20.38

Poverty ratio (%) 0.0018

0-1.5 44.9 44.16 40.98

1.5-3.5 25.1 24.9 27.42

>3.5 29.9 30.93 31.59

BMI (kg/m², %) <0.0001

<25 77.1 72.15 82.2

25-29.9 12.6 15.5 8.94

≥30 10.3 12.35 8.85

Abdominal obesity (%) 0.1825

No 90.1 88.18 89.02

Yes 9.9 11.82 10.98

Drinking status (%) <0.0001

Never 22 21.76 20.23

Former 10.5 9.32 18.6

Mild 27 26.17 34.07

Moderate 15.3 16.05 9.04

Heavy 25.2 26.7 18.06

Smoking status (%) <0.0001

Never 62.6 65.57 53.53

Former 17.2 16.58 24.13

Now 20.2 17.85 22.34

Hypertension (%) <0.0001

No 92.6 94.31 89.17

Yes 7.4 5.69 10.83

Diabetes (%) <0.0001

No 98.5 98.49 96.16

Yes 1.5 1.51 3.84

SII (Mean±SD,1,000cells/µl) 437.8 ± 300.6 461.99 ± 296.11 455.29 ± 293.16 0.2894

2.The definition of CKD usually requires at least 2 eGFR or uACR values obtained at least 3 months apart. It appears this study had single values for both eGFR and uACR which may affect the classification of CKD. Some of the individuals may have an AKI, thereby causing an overestimation of CKD. AKI, on its own, is an inflammatory condition which may affect SII values. This may invalidate our findings.

Reply: Thank you for your professional advice, which has been of great help to the improvement of our article. As you pointed out, for the diagnosis of CKD, it is usually more accurate to have at least 2 eGFR or uACR values at least 3 months apart, but we are sorry that the NHANES database is a cross-sectional study with only one test value, which is also a limitation of many cohorts or databases. In addition, AKI is not yet clear in this database, so we have added it to the limitations in the discussion section.(See red in discussion for details)

3.It appear the 2009 CKD-EPI equation (with race factor) was used for this analysis. This has been shown to inaccurately estimate eGFR. The more recent (and accurate) revision of the equation (DOI: 10.1056/NEJMoa2102953), should be used. The number of participants with CKD will change when the new equation is applied. This is the most important limitation of this study and should be addressed.

Reply: Thank you very much for your valuable comments. Due to the incomplete follow-up data of the 2019-2022 NHANES database, this study only included the data of 2003-2018, and used the earlier version (2009) for formula selection. Based on your valuable comments, we have carefully studied and compared the new formula of 2021 with the formula of 2009, and found that the accuracy of the formula of 2021 is slightly lower than that of 2009 CKD-EPI creatinine formula【1-2】, so we hope to continue to use the formula of 2009.

【1】Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953 (IF: 158.5, Q1)

【2】Hsu CY, Yang W, Parikh RV, et al. Race, Genetic Ancestry, and Estimating Kidney Function in CKD. N Engl J Med. 2021;385(19):1750-1760. doi:10.1056/NEJMoa2103753 (IF: 158.5, Q1)

4. Is there a statistical trend for SII across the 5 stages of CKD? It would be good to investigate for this.

Reply: Thank you very much for your valuable comments. We re-completed a statistical analysis of the relationship between CKD stage(G1,G2,G3a,G3b,G4,G5) and SII. The new results can be seen in supplementary Tables 1&2 and in the sentences marked in red in the results section of the revised manuscript.

Finally

We marked the changes in red in the revised paper.

We have also added references, adding Supplementary Figures 1 and 2.

We have changed the manuscript according to the request using PLOS ONE' s style and added the Funding section.

These comments are all valuable and enable us to greatly improve the quality of our manuscript. We tried our best to improve the manuscript. These changes will not influence the content and framework of the paper. We appreciate for Editors/Reviewers’ warm work earnestly and hope that the corrections will meet with approval.

Please do not hesitate to contact us with any further questions or recommendations.

Once again, thank you very much for your comments and suggestions.

Attachment

Submitted filename: Response letter.docx

Decision Letter 1

Innocent Ijezie Chukwuonye

26 Sep 2023

Association between systemic immune-inflammation index and chronic kidney disease: a population-based study

PONE-D-23-11993R1

Dear Lin Huang

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Innocent Ijezie Chukwuonye, MBBS, FMCP (Internal Medicine)

Academic Editor

PLOS ONE

Acceptance letter

Innocent Ijezie Chukwuonye

3 Oct 2023

PONE-D-23-11993R1

Association between systemic immune-inflammation index and chronic kidney disease: a population-based study

Dear Dr. Ma:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Innocent Ijezie Chukwuonye

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Weighted characteristics of the study population categorized by 5 stages of CKD.

    Continuous variables were expressed as mean ± SD, and P-values were calculated by the weighted linear regression model. Categorical variables are shown as percentages: p-values were calculated by weighted chi-square test. BMI, body mass index; SII, systemic immune-inflammation index; CKD: chronic kidney disease.

    (DOCX)

    S2 Table. Association between SII and 5 stages of CKD.

    Model 1: no covariates were adjusted. Model 2: age, gender, and race were adjusted. Model 3: age, gender, race, marital status, education level, income poverty ratio, BMI, abdominal obesity, drinking status, smoking status, hypertension, and diabetes were adjusted.

    (DOCX)

    S1 Checklist. STROBE statement—Checklist of items that should be included in reports of observational studies.

    (DOCX)

    Attachment

    Submitted filename: Manuscript(2).docx

    Attachment

    Submitted filename: Response letter.docx

    Data Availability Statement

    The full set of NHANES data used for this investigation is accessible to the general public here: https://wwwn.cdc.gov/nchs/nhanes.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES